Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.67 USD | 0.00% | -0.60% | -32.00% |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.00% | 94Cr | |
+26.30% | 4.92TCr | |
+0.27% | 4.21TCr | |
+50.18% | 4.04TCr | |
-5.26% | 2.89TCr | |
+12.47% | 2.61TCr | |
-21.74% | 1.87TCr | |
+8.69% | 1.33TCr | |
+31.68% | 1.23TCr | |
-0.58% | 1.2TCr |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating